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Pharmacovigilance of Biosimilars
Abstract
In lieu of an abstract, here is the article's first paragraph:
Biotech industry forms the backbone of the current pharmaceutical products. Seven out of top ten
anticipated drugs of the industry in 2014 will be biologics [1]. Considering the fast pace growth of the
biotechnological products, there is a parallel demand of biosimilars. As defined by FDA, “A biosimilar is a
biological product that is highly similar to a U.S.-licensed reference biological product notwithstanding
minor differences in clinically inactive components, and for which there are no clinically meaningful
differences between the biological product and the reference product in terms of the safety, purity, and
potency of the product” [2]. Thus these biosimilar products become affordable alternatives to several
biotechnological products, which are going off-patent. Along with the benefit of cost-effective therapy and
scope of further research leading to the possibility of bio-superiors, biosimilars have led to formation of a
whole new branch of biotech industry. However, there are various other concerns that require these
biosimilars to be monitored closely.
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Biotech industry forms the backbone of the current pharmaceutical
products. Seven out of top ten anticipated drugs of the industry in
2014 will be biologics [1]. Considering the fast pace growth of the
biotechnological products, there is a parallel demand of biosimilars.
As defined by FDA, “A biosimilar is a biological product that is highly
similar to a U.S.-licensed reference biological product notwithstanding
minor differences in clinically inactive components, and for which
there are no clinically meaningful differences between the biological
product and the reference product in terms of the safety, purity, and
potency of the product” [2]. Thus these biosimilar products become
affordable alternatives to several biotechnological products, which are
going off-patent. Along with the benefit of cost-effective therapy and
scope of further research leading to the possibility of bio-superiors,
biosimilars have led to formation of a whole new branch of biotech
industry. However, there are various other concerns that require these
biosimilars to be monitored closely.
The European Medicines Agency (EMEA) issued a guideline on
“similar biological medicinal products” in October 2005 and since then
14 biosimilar products have been approved by EMA for the European
market. These include biologics of three major classes: human growth
hormone, granulocyte colony-stimulating factor and erythropoietin
[3]. Considering the need for biosimilars for the current market, U.S.
FDA has also issued draft guidance, recently in 2010, in an attempt to
provide licensure pathway for biosimilars. The guidance aims to assure
the safety, purity and potency of these biosimilars before approval.
Unlike the generic drugs for small molecules, the biosimilars
will undergo stringent regulatory processes. As the biosimilars can
be manufactured in multiple different ways and have human/animal
origin, they can yield to the formation of biological product with
similar efficacy but varied adverse effects to the reference. Thus, unlike
small molecule generics, a biosimilar approval requires clinical studies
to ensure that small manufacturing changes have not altered the
therapeutic efficacy of the biological drug. Further, pharmacovigilance
allows monitoring of adverse effects associated with a particular
marketed biosimilar [4].
World Health Organization (WHO) defines pharmacovigilance
as “the science and activities relating to the detection, assessment,
understanding and prevention of adverse effects or any other drugrelated problem” [5]. Once a drug is released in the market by FDA,
it is monitored for its safety profile. Further, the adverse effects caused
by the drug are reported to generate post-marketing surveillance data.
Post-marketing pharmacovigilance becomes even more critical in
case of biosimilars as there is limited information available regarding
them. Additionally, the effect of such biosimilars on diverse patient
populations with respect to the dosage and duration of therapy needs to
be closely monitored. Due to these reasons, biosimilars are required to
undergo same pharmacovigilance regulations as its reference product.
Thus biosimilars approved by EMEA are required to submit a risk
management plan (RMP) along with the marketing application and
have to provide regular safety update reports after the product is in the
market. The RMP includes the safety profile of the drug and proposes
the prospective pharmacovigilance studies [6].
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Currently, the approved biosimilars of European market are
under strict pharmacovigilance to assure patient safety. Ebbers et
al. [7] reports various pharmacovigilance activities that have been
conducted to monitor the safety of such approved biosimilars. These
efforts includes cohort studies and surveys to monitor the adverse
effects of erythropoietin biosimilars, pharmacovigilance programs and
safety follow-up for long term data regarding the use of granulocyte
colony-stimulating factor and a check on immunogenicity data for
human growth hormone administered to the younger population
[7]. Along with these studies spontaneous monitoring of the adverse
effects serves to be useful. Spontaneous reports originating from the
healthcare providers assist in identifying the biologic responsible for
it, target patient population, severity of the adverse effect and the
need of intervention. Overall, these surveillance studies are capable
of generating information that will not only be useful for the patient
population in Europe but will also provide supporting data to the
scientists in other countries like the U.S. where several biotech/
pharmaceutical companies plan to venture in the field of biosimilars.
In conclusion, pharmacovigilance is an integral part of biosimilar
approval due to the fact that these biologics are unlike small
molecule generics. Pharmacovigilance studies will continue to assist
biotechnological companies to bring safe and efficacious biologics to
the market as the information pool grows regarding the safety profile of
some of the approved biologics.
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